In vitro pharmacokinetic study of the novel anticancer agent E7070: Red blood cell and plasma protein binding in human blood

Anti-Cancer Drugs

Volumn 14, Issue 6, 2003, Pages 405-410

  Van Den Bongard, H J G D ^a,b   Pluim, D ^b   Van Waardenburg, R C A M ^b   Ravic, M ^d   Beijnen, J H ^a,b,c   Schellens, J H M ^b,c  

^a SLOTERVAART HOSPITAL   (Netherlands)

^b Antoni van Leeuwenhoek Hospital   (Netherlands)

^c UTRECHT UNIVERSITY   (Netherlands)

^d EISAI CO LTD   (Japan)

Author keywords

E7070; Plasma protein binding; Red blood cell binding; Sulfonamide anticancer agent

Indexed keywords

ANTINEOPLASTIC AGENT; CARBON 14; INDISULAM; PLASMA PROTEIN; SODIUM AZIDE; SULFONAMIDE; UNCLASSIFIED DRUG;

ARTICLE; CELL ADHESION; CONCENTRATION RESPONSE; DRUG BINDING; DRUG DIFFUSION; DRUG PROTEIN BINDING; DRUG UPTAKE; ERYTHROCYTE; HUMAN; IN VITRO STUDY; ISOTOPE LABELING; NONLINEAR SYSTEM; PARTITION COEFFICIENT; PRIORITY JOURNAL;

ANTINEOPLASTIC AGENTS; BLOOD PROTEINS; ERYTHROCYTES; HUMANS; SULFONAMIDES;

EID: 0042126834     PISSN: 09594973     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001813-200307000-00003     Document Type: Article

References (19)

1. 1 phase of the cell cycle. J Med Chem 1999; 42:3789-3799.
2. Owa T, Okauchi T, Yoshimatsu K, et al. A focused compound library of novel N-(7-indolyl)benzenesulfonamides for the discovery of potent cell cycle inhibitors. Bioorg Med Chem Lett 2000; 10:1223-1226.
3. Maren TH. Relations between structure and biological activity of sulfonamides. Annu Rev Pharmacol Toxicol 1976; 16:309-327.
4. Sherr JC. Cancer cell cycles. Science 1996; 274:1672-1677.
5. Lundberg AS, Weinberg RA. Control of the cell cycle and apoptosis. Eur J Cancer 1999; 35:1886-1894.
6. Ozawa Y, Sugi NH, Nagasu T, et al. E7070, a novel sulfonamide agent with potent antitumor activity in vitro and in vivo. Eur J Cancer 2001; 37:2275-2282.
7. Punt CJA, Fumoleau P, Walle B van de, et al. Phase I and pharmacokinetic study of E7070, a novel sulfonamide, given at a daily times five schedule in patients with solid tumors. A study by the EORTC Early Clinical Studies Group (ECSG). Ann Oncol 2001; 12:1289-1293.
8. Raymond E, Fumoleau P, Roche H, et al. Combined results of 4 phase I and pharmacokinetic (PK) studies of E7070 a novel chloroindolyl-sulfonamide inhibiting the activation of cdk2 and cyclin E. Clin Cancer Res 2000; 40:384 (A2545).
9. van Kesteren Ch, Mathôt RAA, Raymond E, et al. Population pharmacokinetics of the novel anti-cancer agent E7070 during four phase I studies: model building and validation. J Clin Oncol 2002; 20:4065-4073.
10. Ludden TM. Nonlinear pharmacokinetics. Clin Pharmacokinet 1991; 20:429-446.
11. Lin JH, Lin T, Cheng H. Uptake and stereoselective binding of the enantiomers of MK-927, a potent carbonic anhydrase inhibitor, by human RBC in vitro. Pharm Res 1992; 9:339-344.
12. Supuran CT, Briganti F, Tillie S, et al. Carbonic anhydrase inhibitors: Sulfonamides as antitumor agents? Bioorg Med Chem 2001; 9:703-714.
13. Edsall JT. Some perspectives on carbonic anhydrase since 1960. Ann NY Acad Sci 1984; 429:18-25.
14. Egorin MJ, Snyder SW, Pan S, et al. Cellular transport and accumulation of thiotepa. Sem Oncol 1991; 17(suppl 3):7-17.
15. Trapp S, Ashcroft FM. Direct interaction of Na-azide with the K(ATP) channel. Br J Pharmacol 2000; 131:1105-1112.
16. Rosing H, Hillebrand MJX, Ravic M, et al. Determination of E7070 and its metabolite M1 in biological matrices using liquid chromatography coupled with electrospray ionization tandem mass spectrometry. Presented at: 17th (Montreux) Symp Liquid Chromatography (LC/MS; SFC/MS; CE/MS; MS/MS) 2000; A101.
17. van den Bongard HJGD, Pluim D, Rosing H, et al. An excretion balance and pharmacokinetic study of the novel anticancer agent E7070 in cancer patients. Anticancer Drugs 2002; 13:1-8.
18. Lee H-J, Chiou WL. RBC as barriers for drug elimination in the isolated rat liver I. Doxorubicin. Pharm Res 1989; 6:833-839.
19. Chen T-M, Abdelhameed MH, Chiou WL. RBC as a total barrier for renal excretion of hydrochlorothiazide: slow influx and efflux across erythrocyte membranes. J Pharm Sci 1993; 81:212-216.